[go: up one dir, main page]

AU2001253158A1 - Methods of investigating, diagnosing, and treating amyloidosis - Google Patents

Methods of investigating, diagnosing, and treating amyloidosis

Info

Publication number
AU2001253158A1
AU2001253158A1 AU2001253158A AU5315801A AU2001253158A1 AU 2001253158 A1 AU2001253158 A1 AU 2001253158A1 AU 2001253158 A AU2001253158 A AU 2001253158A AU 5315801 A AU5315801 A AU 5315801A AU 2001253158 A1 AU2001253158 A1 AU 2001253158A1
Authority
AU
Australia
Prior art keywords
investigating
diagnosing
methods
treating amyloidosis
amyloidosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001253158A
Inventor
Rudi Hrncic
Maria Schell
Alan Solomon
Jonathan Wall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tennessee Research Foundation
Original Assignee
University of Tennessee Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Tennessee Research Foundation filed Critical University of Tennessee Research Foundation
Publication of AU2001253158A1 publication Critical patent/AU2001253158A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2001253158A 2000-04-05 2001-04-05 Methods of investigating, diagnosing, and treating amyloidosis Abandoned AU2001253158A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19468400P 2000-04-05 2000-04-05
US60/194,684 2000-04-05
PCT/US2001/011043 WO2001077167A2 (en) 2000-04-05 2001-04-05 Methods of investigating, diagnosing, and treating amyloidosis

Publications (1)

Publication Number Publication Date
AU2001253158A1 true AU2001253158A1 (en) 2001-10-23

Family

ID=22718526

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001253158A Abandoned AU2001253158A1 (en) 2000-04-05 2001-04-05 Methods of investigating, diagnosing, and treating amyloidosis

Country Status (5)

Country Link
US (1) US7485616B2 (en)
EP (1) EP1353944A2 (en)
AU (1) AU2001253158A1 (en)
CA (1) CA2404237C (en)
WO (1) WO2001077167A2 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
CA2404237C (en) * 2000-04-05 2010-01-26 University Of Tennessee Research Corporation Methods of investigating, diagnosing, and treating amyloidosis
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
CA2501945A1 (en) * 2002-10-09 2004-04-22 Rinat Neuroscience Corp. Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
WO2005059100A2 (en) * 2003-12-12 2005-06-30 New York University Methods and compositions relating to cystatin c
KR101068289B1 (en) * 2004-07-30 2011-09-28 리나트 뉴로사이언스 코퍼레이션 Antibodies directed against amyloid-beta peptides and methods of use thereof
US7625560B2 (en) 2004-12-15 2009-12-01 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
CA2590337C (en) 2004-12-15 2017-07-11 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
UY29504A1 (en) * 2005-04-29 2006-10-31 Rinat Neuroscience Corp DIRECTED ANTIBODIES AGAINST BETA AMYLOID PEPTIDE AND METHODS USING THE SAME.
CA2625850A1 (en) * 2005-10-17 2007-04-20 Mayo Foundation For Medical Education And Research Methods and materials for producing a generic anti-amyloid immune response in mammals
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
WO2009017467A1 (en) 2007-07-27 2009-02-05 Elan Pharma International Limited Treatment of amyloidogenic diseases
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
JO3076B1 (en) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
HUE025560T2 (en) 2007-12-28 2016-03-29 Prothena Biosciences Ltd Treatment and prophylaxis of amyloidosis
FI20085340A7 (en) * 2008-04-22 2009-10-23 Medixine Oy Health screening and method for implementing a health screening
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US9683017B2 (en) 2014-07-17 2017-06-20 University Tennessee Research Foundation Inhibitory peptides of viral infection
US10213506B2 (en) 2014-08-26 2019-02-26 University Of Tennessee Research Foundation Targeting immunotherapy for amyloidosis
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
WO2017184973A1 (en) * 2016-04-22 2017-10-26 University Of Tennessee Research Foundation Identifying amyloidogenic proteins & amyloidogenic risk
PE20210042A1 (en) 2017-10-06 2021-01-08 Prothena Biosciences Ltd METHODS TO DETECT TRANSTIRETIN
CU24731B1 (en) 2017-10-06 2025-01-15 Prothena Biosciences Ltd ANTI-TRANSTYRETIN ANTIBODIES
MX2020005433A (en) 2017-11-29 2020-08-27 Prothena Biosciences Ltd Lyophilized formulation of a monoclonal antibody against transthyretin.
US20210400932A1 (en) * 2018-11-09 2021-12-30 Neurimmune Ag Patient-derived amyloid xenograft non-human animal model
WO2021168156A1 (en) * 2020-02-20 2021-08-26 Prothena Biosciences Limited Monitoring transthyretin amyloidosis

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3521684A1 (en) * 1985-06-18 1986-12-18 Dr. Müller-Lierheim KG, Biologische Laboratorien, 8033 Planegg METHOD FOR COATING POLYMERS
EP0526511B1 (en) * 1990-04-27 1997-05-28 MCMICHAEL, John Method and composition for treatment of central nervous systems disease states associated with abnormal amyloid beta protein
JP2988635B2 (en) * 1990-09-18 1999-12-13 塩野義製薬株式会社 Monoclonal antibody against human IgE
US5643570A (en) * 1992-05-19 1997-07-01 Xoma Corporation BPI-immunoglobulin fusion proteins
US5750106A (en) * 1993-01-28 1998-05-12 Novartis Ag Human monoclonal antibodies to cytomegalovirus
US5744368A (en) 1993-11-04 1998-04-28 Research Foundation Of State University Of New York Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR)
DE69521700T2 (en) 1994-05-25 2001-10-25 John Mcmichael AGENTS AND METHODS FOR TREATING PLAQUE DISEASES
US5786180A (en) * 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6913745B1 (en) * 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
ATE465178T1 (en) 1998-05-21 2010-05-15 Univ Tennessee Res Foundation METHODS OF AMYLOID REMOVAL USING ANTI-AMYLOID ANTIBODIES
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
CA2404237C (en) * 2000-04-05 2010-01-26 University Of Tennessee Research Corporation Methods of investigating, diagnosing, and treating amyloidosis

Also Published As

Publication number Publication date
US7485616B2 (en) 2009-02-03
WO2001077167A3 (en) 2003-08-28
EP1353944A2 (en) 2003-10-22
WO2001077167A2 (en) 2001-10-18
US20020019335A1 (en) 2002-02-14
CA2404237A1 (en) 2001-10-18
CA2404237C (en) 2010-01-26

Similar Documents

Publication Publication Date Title
AU2001253158A1 (en) Methods of investigating, diagnosing, and treating amyloidosis
AU2001252973A1 (en) Biosensor and related method
AU2001288249A1 (en) Biosensors and methods for their use
AU2001255655A1 (en) Treatment analysis systems and methods
AU2002215125A1 (en) Well treatment method
AU2001245437A1 (en) Lightweight methods and compositions for well treating
AU2001245928A1 (en) Electrolyzer and method of using the same
AU2001264771A1 (en) Well reference apparatus and method
AU2001253065A1 (en) Compositions and methods for treating hair loss using oximyl- and hydroxylamino-prostaglandins
AU2002357801A1 (en) Unitary trifunctional door manager and method
AU2002237774A1 (en) Latch apparatus and method
AU2271400A (en) Composition, kit, method and device for hair treatment
AU2001243394A1 (en) Compounds and methods
AU2001257297A1 (en) Method of authenticating user
AU2001289123A1 (en) Compounds and methods for diagnosing and treating amyloid-related conditions
AU2002227247A1 (en) Biofilm therapy process and elements
AU2001278951A1 (en) Compounds and methods
AU2001218024A1 (en) Methods for treating and preventing alopecia
AU5974999A (en) Hair treatment composition, method and use
AU2931001A (en) Nitrided elements and method of making same
AU2002235277A1 (en) Compounds and methods
AU7894900A (en) Methods and compositions for predicting, diagnosing and treating lipodystrophy
AU2002217915A1 (en) Compositions and methods for diagnosing or treating psoriasis
AU2003209049A1 (en) Methods of treating and diagnosing arthritis
AU2002221222A1 (en) Novel method and use